PET scan study hints at new hope for tough gut cancer
NCT ID NCT04069299
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at 30 adults with a rare, fast-growing type of gut cancer called poorly differentiated neuroendocrine carcinoma. Researchers used a special PET scan (68Ga-DOTATATE) to measure how much of a protein called somatostatin receptor is present on tumors. The goal was to see if enough patients have this protein to make a future treatment called PRRT (peptide receptor radiotherapy) worth testing. The study is complete and provides important information for designing future treatment trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 68Ga-DOTATATE (a radioactive tracer used in PET scans)
- What this could lead to
- If successful, this could show whether a targeted radiation therapy (PRRT) might work for patients with this aggressive cancer.
- What could go wrong
- This is a small, completed imaging study (30 people) that only measures receptor levels—it does not test treatment itself, so any therapy benefit remains uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE; CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H Lee Moffitt Cancer & Research Institute
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a black seed extract boost immunotherapy against a rare cancer?
- New drug cocktail aims to fight rare cancer
- Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers
- Two-Drug combo aims to stall rare gut tumors
- Could a PARP inhibitor boost chemo for tough lung cancer?
- New drug ZG006 takes on chemo in advanced cancer battle